Kairos Pharma CEO letter updates ENV105 trials, DoD grant, and analyst coverage

Kairos Pharma, LTD.

ENV105 in Phase 2 prostate cancer and Phase 1 lung cancer trials; interim efficacy data expected end of Q2 2025.
CSO lab received $876k DoD grant for biomarker study; trial sites expanded to University of Utah and City of Hope.
Developing KROS101 GITR ligand agonist; data presented at AACR, SITC, and upcoming ASCO.
Non-dilutive government grants received; robust IP portfolio; analyst coverage from EF Hutton, Maxim, HC Wainwright, and others.
Financially strong due to recent private placement and non-dilutive funding; attending D. Boral and HC Wainwright conferences.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.